Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Many Back Expansion in Range of CEA Price Tweaks for Pricey Drugs: Chuikyo
Payers and healthcare members of a cost-effectiveness assessment (CEA) panel on October 4 generally supported expanding the range of CEA-based price adjustments for expensive drugs, though one pharmacy member expressed his wariness over drug lag/loss concerns. Towards FY2024, the Central…
To read the full story
Related Article
- Leqembi Likely to Face 15% Price Cut Under Special CEA Rule
July 10, 2025
- Eisai CEO Anticipates Leqembi Approval in Europe and China by March
December 18, 2023
- Leqembi to Cost 2.98 Million Yen per Year, Re-Pricing Might Be Triggered on Patient Upswing
December 14, 2023
- Leqembi to Debut on Dec. 20; Eisai Sees SC Version and Blood Biomarker as Drivers for Wider Use
December 14, 2023
- Leqembi OK’ed for Listing on Dec. 20; Peak Sales Put at 98.6 Billion Yen
December 13, 2023
- Pharma in Dogged Fight against Expansion of CEA Price Tweaks, Flags “Camel’s Nose”
November 29, 2023
- Chuikyo Agrees to Adopt Normal Rules to Price, Re-Price Leqembi
November 16, 2023
- Industry Prods Careful Debate on Creating Separate Rules for Leqembi Re-Pricing
November 9, 2023
- Medical, Long-Term Care Data Linkage Holds Key to CEA: Leqembi Debate
October 30, 2023
- Leqembi’s Initial Pricing Won’t Factor in Benefits in Long-Term Care
October 19, 2023
- Post-Launch Re-Pricing Likely the Focus of Chuikyo Leqembi Discussions
October 5, 2023
- Chuikyo Mixed on Expanding Range of CEA Price Adjustments for Pricey Meds
September 14, 2023
REGULATORY
- Japan Picks 5 COVID Vaccines for NIP Use from October
September 3, 2026
- New MHLW Pharma Chief Puts AI in Regulatory Reviews High on Agenda
September 3, 2026
- MHLW Insurance Chief Vows Thorough Outreach on OTC-Like Drug Charges
September 3, 2026
- MHLW Scraps Routine Reporting for Type 1 Use under Cartagena Act
September 3, 2026
- Japan to Ease Lifetime Blood Donation Ban for Transfusion Recipients
September 3, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…